Biogenvs.BioMarin Pharmaceutical
BIIB vs BMRN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Biogen is about 3.1× larger than BioMarin Pharmaceutical by market cap; Biogen trades at the lower P/E (39.4 vs 144.9); year to date, Biogen leads (+24.1% vs −7.6%).
Side by side
| BIIB | BMRN | |
|---|---|---|
| Market cap | $32.9B | $10.6B |
| Price | $225.71 | $54.80 |
| Today | +3.3% | −0.2% |
| Return YTD | +24.1% | −7.6% |
| Return 1Y | +44.7% | +0.4% |
| Since June 26, 2026 | +4.5% | −7.1% |
| P/E | 39.4 | 144.9 |
| P/S | 3.3 | 3.1 |
| P/B | 1.7 | 1.7 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
BiogenBIIB
Neurological disease is the whole focus, from multiple sclerosis to Alzheimer's, where Leqembi is partnered with Eisai.
Full BIIB profile →BioMarin PharmaceuticalBMRN
Rare genetic disorders define the company. It sells enzyme replacement therapies and Voxzogo for dwarfism, and has taken gene therapy into hemophilia.
Full BMRN profile →More BIIB & BMRN comparisons
Other head-to-heads in the Biotech & innovation segment.